These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4427254)

  • 61. The developability classification system: application of biopharmaceutics concepts to formulation development.
    Butler JM; Dressman JB
    J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bioavailability assessment under quasi- and nonsteady-state conditions II: study designs.
    Yeh KC; Kwan KC
    J Pharm Sci; 1976 Apr; 65(4):512-7. PubMed ID: 1271248
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Generic equivalence and non-equivalence of drugs.
    Smith RN
    Lancet; 1972 Sep; 2(7776):528-30. PubMed ID: 4115582
    [No Abstract]   [Full Text] [Related]  

  • 64. Letter: Addition of drugs to intravenous fluids.
    Davis M
    Med J Aust; 1975 Mar; 1(9):284. PubMed ID: 1128422
    [No Abstract]   [Full Text] [Related]  

  • 65. Proceedings: The line-up on bioavailability.
    Schneller GH
    Rev Can Biol; 1973; 32():Suppl:151-5. PubMed ID: 4777598
    [No Abstract]   [Full Text] [Related]  

  • 66. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Letter: Addition of drugs to intravenous fluids.
    Breckenridge AM; Baker JA
    Lancet; 1976 May; 1(7969):1127-8. PubMed ID: 57530
    [No Abstract]   [Full Text] [Related]  

  • 68. A simple linear model for the simulation of plasma concentration-time curves based on the two-compartment open model.
    Mizuta E
    Chem Pharm Bull (Tokyo); 1984 Mar; 32(3):1096-105. PubMed ID: 6744482
    [No Abstract]   [Full Text] [Related]  

  • 69. Bioavailability testing and clinical significance.
    Ritschel WA
    Pharm Acta Helv; 1974 Mar; 49(2):77-83. PubMed ID: 4850767
    [No Abstract]   [Full Text] [Related]  

  • 70. A new method for constant plasma drug concentrations: application to lidocaine.
    Riddell JG; McAllister CB; Wilkinson GR; Wood AJ; Roden DM
    Ann Intern Med; 1984 Jan; 100(1):25-8. PubMed ID: 6691655
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Determination of drug concentrations in body fluids; possibilities and limitations. I. Determination of plasma levels as a basis for understanding].
    Ariëns EJ; Simonis AM
    Ned Tijdschr Geneeskd; 1980 Jul; 124(29):1192-201. PubMed ID: 6997756
    [No Abstract]   [Full Text] [Related]  

  • 72. Dosage regimen design.
    DeVane CL; Jusko WJ
    Pharmacol Ther; 1982; 17(2):143-63. PubMed ID: 6757976
    [No Abstract]   [Full Text] [Related]  

  • 73. Rapid methods for bioavailability determination utilizing urinary excretion data.
    Niebergall PJ; Sugita ET; Schnaare RL
    J Pharm Sci; 1975 Oct; 64(10):1721-2. PubMed ID: 1185547
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interpretation of plasma concentration-time curves after oral dosing.
    Ronfeld RA; Benet LZ
    J Pharm Sci; 1977 Feb; 66(2):178-80. PubMed ID: 839412
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Biopharmaceutical evaluation of preparations intended for the parenteral route].
    Aiache JM; Aiache S
    Boll Chim Farm; 1983 May; 122(5):213-28. PubMed ID: 6357232
    [No Abstract]   [Full Text] [Related]  

  • 77. Calculating absorption rate constants for drugs with incomplete availability.
    Leeson LJ; Weintraub H
    J Pharm Sci; 1973 Dec; 62(12):1936-41. PubMed ID: 4762161
    [No Abstract]   [Full Text] [Related]  

  • 78. [Biological availability].
    Weber E; Gundert-Remy U
    Arzneimittelforschung; 1975 Jul; 25(7a):1158-62. PubMed ID: 1242346
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Factors influencing plasma drug concentrations.
    Luscombe DK
    J Int Med Res; 1977; 5(1 Suppl):82-97. PubMed ID: 863093
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oral biopharmaceutics-current status and identified gaps of understanding.
    Lennernäs H; Abrahamsson P; Langguth B
    Eur J Pharm Sci; 2014 Jun; 57():98. PubMed ID: 24508580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.